{"Clinical Trial ID": "NCT00455533", "Intervention": ["INTERVENTION 1:", "Ixabepilone", "ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)", "INTERVENTION 2:", "- Paclitaxel", "Paclitaxel 80 mg/m^2 given weekly for 12 weeks"], "Eligibility": ["\u2022 Inclusion criteria", "Invasive primary adenocarcinoma, T2-3, N0-3, M0, with tumour size of 2 cm", "All patients with early breast adenocarcinoma may register regardless of the status of the receptor.", "No prior treatment for breast cancer, excluding treatment for CDIS", "Karnofsky's performance status of 80 - 100", "The left ventricular ejection fraction (LVEF) 50% by echocardiogram or multiple barrier acquisition (MUGA)", "Adequate haematological, hepatic and renal function", "\u2022 Exclusion criteria", "\u2022 Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to prevent pregnancy during and up to 8 weeks after the last dose of the experimental drug", "Pregnant or lactating women", "Inflammatory or metastatic breast cancer", "Infection for breast and/or axillary surgery", "Evidence of initial sensory or motor neuropathy", "Significant history of cardiovascular disease, serious intercurrent diseases or infections, including known immu human immunodeficiency virus (HIV) infection", "Previous history of treatment with anthracycline Allergies to any study medicine or Cremophor\u00ae EL"], "Results": ["Performance measures:", "Percentage of participants receiving a complete pathological response (CPR)", "PCR has not been defined as histological evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of in situ channel carcinoma (CDIS) in the breast.", "Duration: in surgery (4-6 weeks after the last dose of 12 weeks of treatment)", "Results 1:", "Title of the arm/group: Ixabepilone", "Description of the arm/group: ixabepilone 40 mg/m^2 administered intravenously (IV) for 3 hours, every 3 weeks for 4 cycles (12 weeks)", "Total number of participants analysed: 148", "Type of measurement: Number", "Unit of measure: Percentage of participants 24.3 (18.6 to 30.8)", "Results 2:", "Title of the arm/group: Paclitaxel", "Description of the arm/group: paclitaxel 80 mg/m^2 given IV each week for 12 weeks", "Total number of participants analysed: 147", "Type of measurement: Number", "Unit of measure: percentage of participants 25.2 (19.4 to 31.7)"], "Adverse Events": ["Undesirable Events 1:", "Total: 17/145 (11.72%)", "- ANEMIA 0/145 (0.00 %)", "LEUKOPENIA 2/145 (1.38%)", "NEUTROPENIA 1/145 (0.69%)", "LEUKOCYTOSIS 1/145 (0.69%)", "THROMBOCYTOPENIA 1/145 (0.69%)", "NEUTROPENIA FEBRILE 1/145 (0.69%)", "THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00 %)", "DIFFUSION OF INTRAVASCULAR COAGULATION 0/145 (0.00 %)", "- CARDIAC LEAF 1/145 (0.69%)", "1/145 (0.69%)", "Adverse Events 2:", "Total: 11/144 (7.64 per cent)", "ANEMIA 1/144 (0.69%)", "LEUKOPENIA 0/144 (0.00 %)", "NEUTROPENIA 0/144 (0.00 %)", "LEUKOCYTOSIS 0/144 (0.00 %)", "THROMBOCYTOPENIA 0/144 (0.00 %)", "NEUTROPENIA FEBRILE 1/144 (0.69%)", "THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)", "DIFFUSION OF INTRAVASCULAR COAGULATION 1/144 (0.69%)", "- CARDIAC FAILURE 0/144 (0.00 %)", "ATMOSPHERIC FIBRILLATION 0/144 (0.00 %)"]}